Immune Profiling for Cancer Immunotherapy Response

Dartmouth Health

Status: Enrolling

Conditions: Hematologic Malignancy; Blood Cancer; Cancer; Tumor, Solid

Treatments: Diagnostic Test: Methylation Cytometry

Study type: Observational

Funder types: Other

Identifiers

NCT06116032

Study02001227

Details and patient eligibility

About

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
• Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion criteria

• Pregnant women/fetuses/neonates
• Prisoners
• Decision-impaired individuals

Trial design

1,500 participants in 3 patient groups

Standard of Care Checkpoint

Description:

Patients receiving standard of care FDA approved immunotherapy

Treatment:

Diagnostic Test: Methylation Cytometry

Bone Marrow Transplant

Description:

Patients undergoing transplant for hematologic malignancy

Treatment:

Diagnostic Test: Methylation Cytometry

CAR T

Description:

Patients undergoing CAR T therapy

Treatment:

Diagnostic Test: Methylation Cytometry